U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib) June 9, 2022June 21, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA Approves NGS-Based Companion Diagnostic for…FDA Approves Tissue-Based NGS Companion Diagnostic…FDA Approves NGS-Based Companion Diagnostic for EGFR…Roche receives FDA approval for first companion…Roche’s VENTANA PD-L1 (SP263) Assay receives FDA…Roche receives FDA approval for first companion…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
